In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii.
J Antimicrob Chemother
; 67(5): 1167-9, 2012 May.
Article
em En
| MEDLINE
| ID: mdl-22294643
ABSTRACT
OBJECTIVES:
The activity of BAL30072 was compared with that of anti-Acinetobacter reference drugs against meropenem-non-susceptible Acinetobacter baumannii isolates associated with up-regulation of the intrinsic OXA-51-like enzyme or an acquired OXA.METHODS:
Antimicrobial susceptibility testing was investigated by broth microdilution of 310 non-duplicate, meropenem-non-susceptible A. baumannii isolates to BAL30072, amikacin ampicillin/sulbactam, aztreonam, cefepime, colistin, imipenem, levofloxacin, meropenem, rifampicin, tigecycline and tobramycin.RESULTS:
BAL30072 showed greater activity than the ß-lactam comparators, levofloxacin, amikacin, tobramycin and rifampicin. The activity of BAL30072 was comparable to that of tigecycline, with an MIC(50) of 2 mg/L. Elevated BAL30072 MICs were found, but there was no correlation with elevated MICs of the other antimicrobials.CONCLUSIONS:
BAL30072 is a promising new agent with good activity against carbapenem-non-susceptible A. baumannii.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Tiazóis
/
Monobactamas
/
Tienamicinas
/
Resistência beta-Lactâmica
/
Acinetobacter baumannii
/
Antibacterianos
Limite:
Humans
Idioma:
En
Revista:
J Antimicrob Chemother
Ano de publicação:
2012
Tipo de documento:
Article
País de afiliação:
Alemanha